Who are Phase C: Eplerenone's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Eplerenone (Night-time), Eplerenone (Morning).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/phase-c-eplerenone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Phase C: Eplerenone — Competitive Intelligence Brief

Phase C: Eplerenone (Phase C: Eplerenone) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective aldosterone antagonist. Area: Cardiovascular.

marketed Selective aldosterone antagonist Mineralocorticoid receptor (MR) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Phase C: Eplerenone (Phase C: Eplerenone) — National Institute of Cardiology, Warsaw, Poland. Eplerenone is a selective aldosterone antagonist that blocks mineralocorticoid receptors in the kidney and heart, reducing sodium retention and potassium loss.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Phase C: Eplerenone TARGET	Phase C: Eplerenone	National Institute of Cardiology, Warsaw, Poland	marketed	Selective aldosterone antagonist	Mineralocorticoid receptor (MR)
Eplerenone (Night-time)	Eplerenone (Night-time)	Vanderbilt University Medical Center	marketed	Selective aldosterone antagonist (mineralocorticoid receptor antagonist)	Mineralocorticoid receptor (MR)
Eplerenone (Morning)	Eplerenone (Morning)	Vanderbilt University Medical Center	marketed	Selective aldosterone antagonist	Mineralocorticoid receptor (MR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective aldosterone antagonist class)

National Institute of Cardiology, Warsaw, Poland · 1 drug in this class
Vanderbilt University Medical Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Phase C: Eplerenone — Competitive Intelligence Brief. https://druglandscape.com/ci/phase-c-eplerenone. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab